eligibility_summary
Eligible: patients aged 2–25 with neuroblastoma treated at HUS or Oncopole Toulouse between Jan 1, 1998 and Dec 31, 2023, all genders, participant/parent does not oppose data reuse and agrees to a QoL survey. Exclude: patients/parents who oppose participation, specific clinical forms of neuroblastoma, and those with interfering treatments or comorbidities.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Drug/intervention: Dinutuximab beta (DNB, Qarziba), a chimeric IgG1 monoclonal antibody. Mechanism of action: binds GD2 (disialoganglioside) abundantly expressed on neuroblastoma cells, mediating tumor cell killing primarily via Fc-dependent antibody‑dependent cell-mediated cytotoxicity (ADCC, engaging NK cells and macrophages/monocytes), complement-dependent cytotoxicity (CDC), and antibody‑dependent phagocytosis, may also promote apoptosis. Targets: GD2 on neuroblastoma (neural crest–derived) cells, engages innate immune effector pathways (NK cells, macrophages) and the complement cascade. Trial type: observational study comparing patient pathways, costs, and quality of life for dinutuximab beta administration at two French centers (hospital vs hospital-at-home), no new therapeutic tested.